. Author manuscript; available in PMC: 2022 Oct 21.

Published in final edited form as: Arthritis Care Res (Hoboken). 2021 Dec 27;74(2):179–186. doi: 10.1002/acr.24446

Table 4.

Quality measures, number of eligible patients, and overall performance

Quality measure	Eligible patients, no.	Overall performance, no. (%)	Practices included in practice-level analysis, no.^*	Practice-level performance, 25th–75th percentile
Renal disease screening	27,369	10,823 (39.5)	164	4.1–60.9
Blood pressure assessment	27,567	26,037 (94.4)	165	96.7–100
Blood pressure uncontrolled	26,037	4,612 (17.7)	152	7.9–26.0
Hydroxychloroquine prescription	27,486	19,647 (71.5)	165	64.9–80.0
Safe hydroxychloroquine dosing	19,647	12,172 (62.0)	163	77.3–95.5
Prolonged glucocorticoid use of >7.5 mg	27,567	5,085 (18.5)	165	10.7–22.1
Composite process measure^†	27,567	7,626 (27.7)	165	1.2–42.8

Practice-level analysis included only practices reporting on ≥20 patients.

^†

Composite process measure includes renal disease screening, blood pressure assessment, hydroxychloroquine prescription, and safe hydroxychloroquine dosing.